Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

Author:

Paton Nicholas I,Musaazi Joseph,Kityo Cissy,Walimbwa Stephen,Hoppe Anne,Balyegisawa Apolo,Asienzo Jesca,Kaimal Arvind,Mirembe Grace,Lugemwa Abbas,Ategeka Gilbert,Borok Margaret,Mugerwa Henry,Siika Abraham,Odongpiny Eva Laker A,Castelnuovo Barbara,Kiragga Agnes,Kambugu Andrew,Kambugu Andrew,Kaimal Arvind,Castelnuovo Barbara,Kiiza Daniel,Asienzo Jesca,Kisembo John,Nsubuga John,Okwero Max,Muyise Rhona,Kityo Cissy,Nasaazi Claire,Nakiboneka Dridah L.,Mugerwa Henry,Namusanje Josephine,Najjuuko Theresa,Masaba Timothy,Serumaga Timothy,Alinaitwe Adolf,Arinda Allan,Rweyora Angela,Ategeka Gilbert,Kangah Mary Goretti,Lugemwa Abbas,Kasozi Mariam,Tukumushabe Phionah,Akunda Rogers,Makumbi Shafic,Musumba Sharif,Myalo Sula,Ahuura John,Namusisi Annet Mary,Kibirige Daniel,Kiweewa Francis,Mirembe Grace,Mabonga Habert,Wandege Joseph,Nakakeeto Josephine,Namubiru Sharon,Nansalire Winfred,Siika Abraham Mosigisi,Kwobah Charles Meja,Mboya Chris Sande,Mokaya Martha Mokeira Bisieri,Karoney Mercy Jelagat,Cheruiyot Priscilla Chepkorir,Cherutich Salinah,Njuguna Simon Wachira,Kirui Viola Cherotich,Borok Margaret,Chidziva Ennie,Musoro Godfrey,Hakim James,Bhiri Joyline,Phiri Misheck,Mudzingwa Shepherd,Manyanga Tadios,Kiragga Agnes,Banegura Anchilla Mary,Hoppe Anne,Balyegisawa Apolo,Agwang Betty,Isaaya Brian,Tumwine Constantine,Odongpiny Eva Laker A.,Asienzo Jesca,Musaazi Joseph,Paton Nicholas,Senkungu Peter,Walimbwa Stephen,Kamara Yvonne,Amperiize Mathius,Allen Elizabeth,Opondo Charles,Mohammed Perry,van Rein-van der Horst Willemijn,Van Delft Yvon,Boateng Fafa Addo,Namara Doreen,Kaleebu Pontiano,Ojoo Sylvia,Bwakura Tapiwanashe,Katana Milly,Venter Francois,Phiri Sam,Walker Sarah

Funder

Janssen Pharmaceuticals

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference29 articles.

1. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings;Gilks;Lancet,2006

2. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach,2021

3. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial;Aboud;Lancet Infect Dis,2019

4. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV,2018

5. Dolutegravir as first- or second-line treatment for HIV-1 infection in children;Turkova;N Engl J Med,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3